Venlo, the Netherlands, April 14, 2023 (GLOBE NEWSWIRE) QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAseq Targeted cfDNA Ultra Panels that will enable researchers
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December
First partnership in the new QIAseq Platform Partnership to increase compatibility of QIAGEN NGS kits with third-party digital data-sharing and analytics companies Bringing together QIAGEN's
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced a new partnership with QIAGEN N.V. (NYSE: QGEN) that will pair QIAseq reagent technology with
Certification of QuantiFERON-TB Gold Plus under more stringent EU regulation, classified under Class CCertification marks milestone in QIAGEN’s transition to full compliance with new EU regulations for IVD performance and safetyQIAGEN will ensure continuous supply of QuantiFERON-TB Gold PlusVENLO, The Netherlands (.